These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19909586)

  • 41. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials.
    Martins WP; Ferriani RA; Navarro PA; Nastri CO
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):144-51. PubMed ID: 25854891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
    Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
    Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: a retrospective cohort study.
    Golbasi H; Ince O; Golbasi C; Ozer M; Demir M; Yilmaz B
    J Obstet Gynaecol; 2019 Feb; 39(2):157-163. PubMed ID: 30280612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gonadotrophin-releasing hormone antagonists: will they replace the agonists?
    Felberbaum RE; Diedrich K
    Reprod Biomed Online; 2003; 6(1):43-53. PubMed ID: 12626142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection.
    Isikoglu M; Ozgur K; Oehninger S
    J Reprod Med; 2007 Jul; 52(7):639-44. PubMed ID: 17847764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Administration effects of single-dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta-analysis of randomized controlled trials.
    Song M; Liu C; Hu R; Wang F; Huo Z
    Exp Ther Med; 2020 Jan; 19(1):786-796. PubMed ID: 31885714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
    Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
    Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing stimulation requirements and final outcome between early follicular and mid luteal pituitary suppression in the long gonadotropin releasing hormone agonist protocol.
    Sarhan A; Harira M; Elshazly S; Nouh A
    JBRA Assist Reprod; 2016 May; 20(2):59-61. PubMed ID: 27244762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Luteal-long GnRH agonist versus flexible-multidose GnRH antagonist protocols for overweight and obese patients who underwent ICSI.
    Esinler I; Bozdag G; Esinler D; Lale KS; Yarali H
    J Obstet Gynaecol; 2015 Apr; 35(3):297-301. PubMed ID: 25244592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
    Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
    Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.